New drug cocktail aims to stall Hard-to-Treat prostate cancer

NCT ID NCT05502315

Ongoing Disease control Sponsor: Rana McKay, MD Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 09, 2026 · Updated 4 times

Summary

This phase 2 trial is testing a combination of two drugs—cabozantinib (a pill) and nivolumab (an infusion)—in 47 men with metastatic castration-resistant prostate cancer, a type that has stopped responding to hormone therapy. The main goal is to see if the treatment can delay cancer growth or spread. Researchers will also measure PSA levels and tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cabozantinib (Cabometyx) and nivolumab (Opdivo)
What this could lead to: If successful, this combination could offer a new treatment option to slow cancer progression in men with advanced prostate cancer that no longer responds to hormone therapy.
What could go wrong: This is an early phase 2 trial with only 47 participants and no comparison group, so results may not apply broadly. Side effects from the drug combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic malignant neoplasm metastatic prostate carcinoma Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CANCER METASTATIC CANCER

Contacts and locations

Locations

University of California San Diego

La Jolla, California, 92093, United States
University of Chicago Medical Center

Chicago, Illinois, 60637, United States
University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States
University of Wisconsin

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.